Mode
Text Size
Log in / Sign up

Thrombosis

Part of Embolism and Thrombosis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Thrombosis

24 trials tracked for Thrombosis: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 764 citations.

24Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 9 Phase 1 5 Other / NA 4
  1. Phase 3 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) Completed · 764 cited
  2. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 280 cited
  3. Phase 3 Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure Completed · 92 cited
  4. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  5. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  6. Phase 4 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed
Show 18 more trials
  1. Phase 2 Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement Completed
  2. Phase 2 Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis Completed
  3. Phase 2 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" Completed
  4. Phase 2 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer Completed
  5. Phase 2 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Completed
  6. Phase 2 Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis Completed
  7. Phase 2 A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation Completed
  8. Phase 2 Heart and Hands Study II: A Retrospective Data Collection & Analysis Project Completed
  9. Phase 2 A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery Completed
  10. Phase 1 Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects Completed
  11. Phase 1 Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects Completed
  12. Phase 1 Bioavailability of Apixaban Crushed Tablet Completed
  13. Phase 1 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Completed
  14. Phase 1 Sildenafil To Prevent Clot Completed
  15. N/A A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters Completed
  16. N/A Pediatric Catheter-related Thrombosis Imaging Study Completed
  17. N/A Heparin and the Reduction of Thrombosis (HART) Trial Completed
  18. N/A Hemodialysis Access Surveillance Evaluation Study Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Thrombosis: what the trials found

Clinical evidence regarding pharmacological interventions for thrombosis includes the use of Clopidogrel, which demonstrated a significant change in maximal platelet aggregation (p<0.001) compared to Ticagrelor, which showed no significant change (p=0.75) 1. Other established trials evaluated Desirudin 3, Apixaban [7, 12, 19], and Rivaroxaban 6.

BAY 59-7939 was shown to significantly reduce the composite of fatal or non-fatal symptomatic recurrent venous thromboembolism (p=0.0001) and the composite of primary efficacy outcomes including myocardial infarction, ischemic stroke, or systemic non-CNS embolism (p<0.0001), while not showing a statistically significant difference in first treatment-emergent major bleeding (p=0.3235) 4.

In specific clinical contexts, Acetylsalicylic acid was associated with a significant reduction in the rate of patients with at least one prosthetic leaflet with >50% motion reduction (p=0.01) and an improvement in aortic transvalvular mean pressure gradient (p=0.01) 5. Rivaroxaban data included measurements of absolute prothrombin time (PT) post-dose 6.

Recent results — preliminary, needs further review

  • AB002 Dose 1 8
  • AB023- Dose 1 9
  • BMS-986141 10
  • SoftSeal Hemostatic Pad 11
  • DU-176b (various doses/studies) [13, 14, 15]

For the clinician treating this condition

  • Clopidogrel demonstrates a statistically significant effect on maximal platelet aggregation compared to Ticagrelor in specific cohorts 1.
  • BAY 59-7939 significantly reduces the incidence of symptomatic recurrent venous thromboembolism and associated major cardiovascular events without a significant increase in major bleeding 4.
  • Acetylsalicylic acid is associated with improved motion metrics and pressure gradients in patients with prosthetic leaflets 5.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Embolism and Thrombosis

Related studies from across the Embolism and Thrombosis family.

Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care
Radiology & Imaging RCT
Endovascular therapy reduces post-thrombotic syndrome severity by 2.0 points compared to standard care Endovascular Therapy Improves Quality of Life for Post-Thrombotic Syndrome
This randomized controlled trial of 225 patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction found that endo…
A new trial shows that endovascular therapy can reduce the severity of post-thrombotic syndrome and improve daily quality of life.
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults
Rheumatology Meta-analysis
Systematic review and meta-analysis of machine learning models for deep vein thrombosis prediction in hospitalized adults Machine learning models predict blood clots in hospitalized adults with high accuracy
This systematic review and meta-analysis synthesized evidence on machine learning-based prediction models for deep vein thrombosis in hospit…
A new analysis of 17 studies shows machine learning models can predict deep vein thrombosis in hospitalized patients with an accuracy score …
Meta-analysis finds modest PTS reduction with compression stockings after DVT
Rheumatology Meta-analysis
Meta-analysis finds modest PTS reduction with compression stockings after DVT Long-term stockings lower risk of post-thrombotic syndrome in deep vein thrombosis patients
This meta-analysis of 1,775 patients with deep vein thrombosis evaluated long-term graduated compression stockings. It found a modest reduct…
A large review found long-term compression stockings modestly reduce the risk of post-thrombotic syndrome in people with deep vein thrombosi…
Meta-analysis finds education lowers DVT risk after orthopedic surgery
Primary Care & Family Medicine Meta-analysis
Meta-analysis finds education lowers DVT risk after orthopedic surgery Teaching patients about DVT cuts risk after orthopedic surgery
This meta-analysis of six studies in orthopedic surgery patients found that education-based interventions were associated with a significant…
A review of studies finds that educating patients about deep vein thrombosis after orthopedic surgery can significantly lower their risk of …
External validation of three DVT prediction models in 1,270 acute stroke patients
Cardiology Meta-analysis
External validation of three DVT prediction models in 1,270 acute stroke patients Three DVT prediction models showed varying accuracy in a single-center stroke study
This single-center spatial validation cohort study assessed three deep vein thrombosis (DVT) prediction models in 1,270 patients with acute …
The Lu Qiufang model outperformed others with 82.1% accuracy in predicting deep vein thrombosis among 1,270 acute stroke patients at a Shenz…
Asthma associated with increased odds of venous thromboembolism, pulmonary embolism, and deep vein thrombosis in observational studies
Allergy & Immunology Meta-analysis
Asthma associated with increased odds of venous thromboembolism, pulmonary embolism, and deep vein thrombosis in observational studies Asthma Linked to Higher Risk of Blood Clots in Observational Data
This meta-analysis of observational studies involving patients with asthma found a statistically significant association between asthma and …
People with asthma face a 1.61 times higher risk of blood clots, with the danger of pulmonary embolism rising 2.41 times and deep vein throm…
Regional anesthesia with propofol sedation versus general anesthesia in unilateral total knee arthroplasty patients
Rheumatology Cohort
Regional anesthesia with propofol sedation versus general anesthesia in unilateral total knee arthroplasty patients Numb Legs, Faster Walks: New Knee Surgery Data
This retrospective cohort study evaluated 250 patients undergoing unilateral total knee arthroplasty to compare regional anesthesia with mon…
New knee surgery data shows regional anesthesia leads to faster walking and fewer readmissions without increasing dangerous blood clot risk.
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE
Cardiology FDA Approval
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE FDA approves a new blood thinner called Xarelto for several heart and clot conditions
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.